Dolasetron mesylate

Phase 3Small molecule

GGary Morrow

Dolasetron mesylate is one of 62 small molecule programs targeting Nausea and vomiting. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nausea and VomitingActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Nausea and VomitingPhase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

408 competitors in Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

40 2

Oncovin

EEastern Cooperative Oncology Group

Phase 3

78 3

Elspar

DDutch Childhood Oncology Group

Phase 3

47 4

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

43 5

Zyloprim

Alnylam Pharmaceuticals

Phase 3

14 6

Medrol

Pfizer

Phase 3

13 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

26 8

Arranon

Novartis

Phase 3

8 9

Tepadina

Alnylam Pharmaceuticals

Phase 3

5 10

Velcade

SShilpa Grover, MD, MPH

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nausea and vomiting3 trials

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

Terminated·UUniversity of Southern California·N/A·NCT02550119·19 enrolled

Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy

Completed·GGary Morrow·Phase 2·NCT00003817·700 enrolled

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Completed·VVanderbilt University·N/A·NCT02625181·27,034 enrolled

Nausea1 trial

Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

Completed·GGary Morrow·Phase 3·NCT00020657

Acute Lymphoblastic Leukemia1 trial

Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia

Recruiting·—··NCT06756022·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Dolasetron mesylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dolasetron mesylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dolasetron mesylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gary Morrow company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGary Morrow

Dolasetron mesylate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nausea and vomiting3 trials

Nausea1 trial

Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News